Inxmed plans to go public in Hong Kong
August 29, 2025
Source: drugdu
93
According to the Hong Kong Stock Exchange's official website, InxBio has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities and CCB International acting as joint sponsors. Founded in 2017, InxBio is a late-stage clinical-stage biotech company dedicated to improving current oncology treatments, which have limited efficacy. Its mission is to address the core challenge of cancer treatment: drug resistance caused by tumor defenses.
Comment: Inspiron Biopharma plans to list in Hong Kong, focusing on addressing drug resistance in tumors. Its core products have potential. However, the company's products are not commercialized, and it continues to lose money. Its capital needs are substantial, and its listing and profitability are uncertain.
https://finance.eastmoney.com/a/202508273495486977.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
